Elite Pharmaceuticals, Inc. Logo

Elite Pharmaceuticals, Inc.

ELTP

(2.2)
Stock Price

0,55 USD

24.29% ROA

-12.2% ROE

22x PER

Market Cap.

430.833.291,00 USD

14.44% DER

0% Yield

-8.98% NPM

Elite Pharmaceuticals, Inc. Stock Analysis

Elite Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Elite Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (15.11%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 ROA

The stock's ability to make a lot of money from its assets shows that it is very profitable, making it a good choice for people who want to invest and make a lot of money.

3 DER

The stock has a minimal amount of debt (26%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (132), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

6 PBV

The stock's elevated P/BV ratio (5.12x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

11 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Elite Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Elite Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Buy
4 Stoch RSI Sell

Elite Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Elite Pharmaceuticals, Inc. Revenue
Year Revenue Growth
1999 200.000
2000 10.315 -1838.92%
2001 95.246 89.17%
2002 1.197.507 92.05%
2003 630.310 -89.99%
2004 258.250 -144.07%
2005 301.480 14.34%
2006 550.697 45.25%
2007 1.143.841 51.86%
2008 1.413.119 19.06%
2009 2.274.825 37.88%
2010 3.344.298 31.98%
2011 4.265.963 21.61%
2012 2.424.118 -75.98%
2013 3.403.525 28.78%
2014 4.601.376 26.03%
2015 5.015.246 8.25%
2016 12.498.332 59.87%
2017 9.637.715 -29.68%
2018 7.458.711 -29.21%
2019 7.568.508 1.45%
2020 17.994.639 57.94%
2021 25.380.749 29.1%
2022 32.262.117 21.33%
2023 34.155.114.000 99.91%
2024 56.628.740 -60214.1%
2024 56.625.128 -0.01%
2025 75.212.252 24.71%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Elite Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1999 1.300.000
2000 1.988.649 34.63%
2001 1.475.487 -34.78%
2002 1.609.108 8.3%
2003 2.013.579 20.09%
2004 2.075.074 2.96%
2005 2.698.641 23.11%
2006 4.343.890 37.88%
2007 6.085.888 28.62%
2008 5.795.779 -5.01%
2009 3.631.425 -59.6%
2010 794.433 -357.11%
2011 1.385.211 42.65%
2012 1.735.689 20.19%
2013 975.250 -77.97%
2014 3.959.316 75.37%
2015 14.727.472 73.12%
2016 12.428.783 -18.49%
2017 8.301.693 -49.71%
2018 9.621.365 13.72%
2019 7.599.820 -26.6%
2020 5.532.462 -37.37%
2021 5.112.542 -8.21%
2022 4.051.349 -26.19%
2023 6.200.163.000 99.93%
2024 10.473.396 -59099.17%
2024 6.883.351 -52.16%
2025 8.654.108 20.46%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Elite Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1999 0
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 2.146.895 100%
2010 1.841.425 -16.59%
2011 876.014 -110.2%
2012 1.410.192 37.88%
2013 1.559.334 9.56%
2014 2.188.672 28.75%
2015 3.164.159 30.83%
2016 3.236.540 2.24%
2017 2.441.181 -32.58%
2018 2.577.042 5.27%
2019 3.219.915 19.97%
2020 3.411.935 5.63%
2021 3.336.226 -2.27%
2022 4.478.356 25.5%
2023 5.122.272.000 99.91%
2024 6.303.940 -81155.09%
2024 7.305.035 13.7%
2025 8.085.932 9.66%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Elite Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
1999 -1.700.000
2000 -2.963.070 42.63%
2001 -2.157.359 -37.35%
2002 -1.175.288 -83.56%
2003 -2.978.450 60.54%
2004 -2.740.789 -8.67%
2005 -4.762.623 42.45%
2006 -5.738.940 17.01%
2007 -5.205.993 -10.24%
2008 -5.234.504 0.54%
2009 -5.848.588 10.5%
2010 -1.426.647 -309.95%
2011 -402.285 -254.64%
2012 -1.481.986 72.86%
2013 -1.577.293 6.04%
2014 -4.762.887 66.88%
2015 -15.889.976 70.03%
2016 -256.333 -6098.96%
2017 -6.628.783 96.13%
2018 -8.037.363 17.53%
2019 -7.880.322 -1.99%
2020 -762.828 -933.04%
2021 3.629.628 121.02%
2022 6.505.545 44.21%
2023 3.288.563.000 99.8%
2024 9.048.584 -36243.4%
2024 12.319.780 26.55%
2025 17.691.200 30.36%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Elite Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
1999 200.000
2000 10.315 -1838.92%
2001 95.246 89.17%
2002 1.197.507 92.05%
2003 630.310 -89.99%
2004 258.250 -144.07%
2005 301.480 14.34%
2006 550.697 45.25%
2007 312.591 -76.17%
2008 388.608 19.56%
2009 810.257 52.04%
2010 1.038.535 21.98%
2011 1.590.845 34.72%
2012 1.410.444 -12.79%
2013 1.088.371 -29.59%
2014 1.365.270 20.28%
2015 2.001.654 31.79%
2016 8.014.170 75.02%
2017 3.739.310 -114.32%
2018 3.947.588 5.28%
2019 2.867.530 -37.67%
2020 7.978.784 64.06%
2021 11.867.138 32.77%
2022 14.795.354 19.79%
2023 16.594.021.000 99.91%
2024 25.788.316 -64247.05%
2024 24.977.155 -3.25%
2025 32.196.264 22.42%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Elite Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
1999 -1.700.000
2000 -2.976.392 42.88%
2001 -13.964.981 78.69%
2002 -1.774.527 -686.97%
2003 -4.061.422 56.31%
2004 -6.514.217 37.65%
2005 -5.906.890 -10.28%
2006 -6.883.914 14.19%
2007 -11.803.512 41.68%
2008 -13.893.060 15.04%
2009 -6.604.708 -110.35%
2010 -8.056.874 18.02%
2011 -13.582.159 40.68%
2012 -15.058.274 9.8%
2013 1.487.928 1112.03%
2014 -96.575.271 101.54%
2015 28.929.674 433.83%
2016 -683.012 4335.6%
2017 3.811.181 117.92%
2018 -3.673.172 203.76%
2019 -9.279.321 60.42%
2020 -2.240.351 -314.19%
2021 5.088.421 144.03%
2022 8.898.245 42.82%
2023 4.409.902.000 99.8%
2024 59.738.404 -7282.02%
2024 20.108.631 -197.08%
2025 2.463.092 -716.4%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Elite Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1999 0
2000 0 0%
2001 -2 100%
2002 0 0%
2003 0 0%
2004 -1 0%
2005 0 0%
2006 0 0%
2007 -1 0%
2008 -1 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 4 100%
2024 0 0%
2024 0 0%
2025 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Elite Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
1999 -2.600.000
2000 -4.084.724 36.35%
2001 -2.179.917 -87.38%
2002 -1.916.084 -13.77%
2003 -3.253.199 41.1%
2004 -3.675.017 11.48%
2005 -4.911.346 25.17%
2006 -5.073.829 3.2%
2007 -9.868.493 48.59%
2008 -10.354.560 4.69%
2009 -4.585.960 -125.79%
2010 -1.461.152 -213.86%
2011 164.865 986.27%
2012 -1.062.707 115.51%
2013 -2.147.995 50.53%
2014 -4.777.321 55.04%
2015 -17.100.104 72.06%
2016 -4.714.250 -262.73%
2017 -8.988.715 47.55%
2018 -5.084.038 -76.8%
2019 -6.811.890 25.37%
2020 -1.828.774 -272.48%
2021 2.863.880 163.86%
2022 6.009.748 52.35%
2023 -2.397.914 350.62%
2024 -4.091.211 41.39%
2024 -235.938 -1634.02%
2025 1.465.936 116.09%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Elite Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
1999 -1.500.000
2000 -2.778.850 46.02%
2001 -1.905.984 -45.8%
2002 -1.568.887 -21.49%
2003 -2.573.714 39.04%
2004 -3.658.321 29.65%
2005 -4.883.503 25.09%
2006 -4.625.549 -5.58%
2007 -8.314.268 44.37%
2008 -9.834.277 15.46%
2009 -4.540.068 -116.61%
2010 -1.364.748 -232.67%
2011 1.552.815 187.89%
2012 -394.082 494.03%
2013 -1.943.409 79.72%
2014 -4.216.875 53.91%
2015 -15.103.233 72.08%
2016 -2.765.421 -446.15%
2017 -7.883.861 64.92%
2018 -4.809.191 -63.93%
2019 -6.792.760 29.2%
2020 -1.793.821 -278.68%
2021 3.193.861 156.16%
2022 6.508.314 50.93%
2023 3.338.704 -94.94%
2024 -3.281.558 201.74%
2024 -235.938 -1290.86%
2025 3.144.463 107.5%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Elite Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
1999 1.100.000
2000 1.305.874 15.77%
2001 273.933 -376.71%
2002 347.197 21.1%
2003 679.485 48.9%
2004 16.696 -3969.75%
2005 27.843 40.04%
2006 448.280 93.79%
2007 1.554.225 71.16%
2008 520.283 -198.73%
2009 45.892 -1033.71%
2010 96.404 52.4%
2011 1.387.950 93.05%
2012 668.625 -107.58%
2013 204.586 -226.82%
2014 560.446 63.5%
2015 1.996.871 71.93%
2016 1.948.829 -2.47%
2017 1.104.854 -76.39%
2018 274.847 -301.99%
2019 19.130 -1336.73%
2020 34.953 45.27%
2021 329.981 89.41%
2022 498.566 33.81%
2023 5.736.618 91.31%
2024 809.653 -608.53%
2024 0 0%
2025 1.678.527 100%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Elite Pharmaceuticals, Inc. Equity
Year Equity Growth
1999 2.800.000
2000 5.564.603 49.68%
2001 9.180.254 39.39%
2002 8.153.884 -12.59%
2003 5.426.501 -50.26%
2004 4.048.192 -34.05%
2005 5.702.301 29.01%
2006 9.773.645 41.66%
2007 3.510.548 -178.41%
2008 10.549.321 66.72%
2009 5.943.081 -77.51%
2010 -10.597.865 156.08%
2011 -17.871.280 40.7%
2012 -14.983.682 -19.27%
2013 -8.673.385 -72.75%
2014 -81.198.152 89.32%
2015 -34.731.086 -133.79%
2016 11.163.478 411.11%
2017 25.664.037 56.5%
2018 18.475.512 -38.91%
2019 11.396.096 -62.12%
2020 10.655.821 -6.95%
2021 16.151.929 34.03%
2022 25.222.027 35.96%
2023 28.960.260 12.91%
2024 57.582.818 49.71%
2024 45.094.447 -27.69%
2025 58.250.920 22.59%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Elite Pharmaceuticals, Inc. Assets
Year Assets Growth
1999 3.100.000
2000 9.162.383 66.17%
2001 12.350.301 25.81%
2002 12.724.498 2.94%
2003 8.696.222 -46.32%
2004 7.853.434 -10.73%
2005 9.245.292 15.05%
2006 15.702.241 41.12%
2007 9.696.329 -61.94%
2008 15.310.270 36.67%
2009 10.920.148 -40.2%
2010 10.606.663 -2.96%
2011 11.787.862 10.02%
2012 10.311.717 -14.32%
2013 11.125.133 7.31%
2014 24.317.722 54.25%
2015 25.920.279 6.18%
2016 31.878.550 18.69%
2017 34.311.142 7.09%
2018 30.882.608 -11.1%
2019 24.401.934 -26.56%
2020 24.956.580 2.22%
2021 26.189.492 4.71%
2022 35.148.898 25.49%
2023 40.896.018 14.05%
2024 83.653.536 51.11%
2024 70.718.953 -18.29%
2025 87.846.005 19.5%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Elite Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
1999 300.000
2000 3.597.780 91.66%
2001 3.170.047 -13.49%
2002 4.570.614 30.64%
2003 3.269.721 -39.79%
2004 3.805.242 14.07%
2005 3.542.991 -7.4%
2006 5.928.596 40.24%
2007 6.185.781 4.16%
2008 4.760.949 -29.93%
2009 4.977.067 4.34%
2010 21.204.528 76.53%
2011 29.659.142 28.51%
2012 25.295.399 -17.25%
2013 19.798.518 -27.76%
2014 105.515.874 81.24%
2015 60.651.365 -73.97%
2016 20.715.072 -192.79%
2017 8.647.105 -139.56%
2018 12.407.096 30.31%
2019 13.005.838 4.6%
2020 14.300.759 9.05%
2021 10.037.563 -42.47%
2022 9.926.871 -1.12%
2023 11.935.758 16.83%
2024 26.070.718 54.22%
2024 25.624.506 -1.74%
2025 29.595.085 13.42%

Elite Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.06
Net Income per Share
0.02
Price to Earning Ratio
22x
Price To Sales Ratio
6.48x
POCF Ratio
168.3
PFCF Ratio
6001.47
Price to Book Ratio
7.4
EV to Sales
6.53
EV Over EBITDA
29.31
EV to Operating CashFlow
169.57
EV to FreeCashFlow
6046.83
Earnings Yield
0.05
FreeCashFlow Yield
0
Market Cap
0,43 Bil.
Enterprise Value
0,43 Bil.
Graham Number
0.15
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0.02
Income Quality
0.13
ROE
0.38
Return On Assets
-0.07
Return On Capital Employed
0.19
Net Income per EBT
0.94
EBT Per Ebit
-0.46
Ebit per Revenue
0.21
Effective Tax Rate
0.06

Margins

Sales, General, & Administrative to Revenue
0.12
Research & Developement to Revenue
0.12
Stock Based Compensation to Revenue
0.13
Gross Profit Margin
0.44
Operating Profit Margin
0.21
Pretax Profit Margin
-0.1
Net Profit Margin
-0.09

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0.97
Capex to Revenue
0.04
Capex to Depreciation
1.42
Return on Invested Capital
272.23
Return on Tangible Assets
0.24
Days Sales Outstanding
112.53
Days Payables Outstanding
25.36
Days of Inventory on Hand
134.56
Receivables Turnover
3.24
Payables Turnover
14.39
Inventory Turnover
2.71
Capex per Share
0

Balance Sheet

Cash per Share
0,01
Book Value per Share
0,05
Tangible Book Value per Share
0.05
Shareholders Equity per Share
0.05
Interest Debt per Share
0.01
Debt to Equity
0.14
Debt to Assets
0.1
Net Debt to EBITDA
0.22
Current Ratio
3.08
Tangible Asset Value
0,05 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
51156222
Working Capital
0,03 Bil.
Intangibles to Total Assets
0.08
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
13380891
Debt to Market Cap
0.02

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Elite Pharmaceuticals, Inc. Dividends
Year Dividends Growth

Elite Pharmaceuticals, Inc. Profile

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.

CEO
Mr. Nasrat Hakim
Employee
64
Address
165 Ludlow Avenue
Northvale, 07647

Elite Pharmaceuticals, Inc. Executives & BODs

Elite Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Nasrat Hakim
Chairman, Chief Executive Officer & President
70
2 Ms. Dianne Will
Vice President of Investor Relations & Corporate Affairs
70
3 Mr. Kirko Kirkov
Chief Commercial Officer
70
4 Dr. George Kenneth Smith J.D., M.B.A., Ph.D.
Vice President of Legal
70
5 Mr. Carter J. Ward CPA, CSCP
Chief Financial Officer
70
6 Mr. Douglas Plassche
Executive Vice President of Operations
70

Elite Pharmaceuticals, Inc. Competitors